Cargando…

Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target o...

Descripción completa

Detalles Bibliográficos
Autores principales: Faizul Huq, AKM, Rahman, Md Fashiur, Islam, Md Azizul, Iqbal, Syed A, Rahman, Azizur, Abdullah, Syed Abul Hassan Md, Al Mahtab, Mamun, Akbar, Sheikh MF
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376598/
https://www.ncbi.nlm.nih.gov/pubmed/32742970
http://dx.doi.org/10.5005/jp-journals-10018-1316
_version_ 1783562069839183872
author Faizul Huq, AKM
Rahman, Md Fashiur
Islam, Md Azizul
Iqbal, Syed A
Rahman, Azizur
Abdullah, Syed Abul Hassan Md
Al Mahtab, Mamun
Akbar, Sheikh MF
author_facet Faizul Huq, AKM
Rahman, Md Fashiur
Islam, Md Azizul
Iqbal, Syed A
Rahman, Azizur
Abdullah, Syed Abul Hassan Md
Al Mahtab, Mamun
Akbar, Sheikh MF
author_sort Faizul Huq, AKM
collection PubMed
description BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target of management COVID-19 is to reduce complications with available management options; this become highly variable from country to country and even within different regions of the same country. AIM AND OBJECTIVE: This observational prospective study represents a single center study in which all patients in this cohort received almost similar medicines and care. MATERIALS AND METHODS: All patients in this cohort (N: 32) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) with variable presenting symptoms. The management strategy included Standard of Care (SoC) and administration of hydroxychloroquine and doxycycline. Out of 32 patients, 9 patients also received favipiravir. All patients were followed until they were discharged after negativity of SARS-CoV-2 confirmed by PCR on two consecutive occasions taken within 2 days. RESULTS: No death has been recorded in this cohort of 32 patients within the study period. The average hospital staying duration was 13.9 days with a range of 8–21 days. All patients were discharged with improvement of subjective symptoms and SARS-CoV-2 negativity. The vital signs (pulse, blood pressure) as well as and levels of electrolyte and blood counts were within normal and acceptable ranges at the time of discharge. CONCLUSION: The study presented here provide and evidence of a real-life situation of management of limited numbers of COVID-19 patients at a tertiary center of Bangladesh. This study inspires optimism that proper diagnosis, establishment of effective inclusion and exclusion criteria, ensuring application of proper SoC with drugs available in Bangladesh may be a practical option for management of COVID-19 in the country. HOW TO CITE THIS ARTICLE: Huq AKMF, Rahman MF, Islam MA, et al. Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. Euroasian J Hepato-Gastroenterol 2020;10(1):31–35.
format Online
Article
Text
id pubmed-7376598
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-73765982020-07-31 Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study Faizul Huq, AKM Rahman, Md Fashiur Islam, Md Azizul Iqbal, Syed A Rahman, Azizur Abdullah, Syed Abul Hassan Md Al Mahtab, Mamun Akbar, Sheikh MF Euroasian J Hepatogastroenterol Original Article BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared as pandemic by World Health Organization (WHO) with increasing morbidity (more than 4.6 million patients) and mortality (300,000 deaths). The world-wide target of management COVID-19 is to reduce complications with available management options; this become highly variable from country to country and even within different regions of the same country. AIM AND OBJECTIVE: This observational prospective study represents a single center study in which all patients in this cohort received almost similar medicines and care. MATERIALS AND METHODS: All patients in this cohort (N: 32) were positive for SARS-CoV-2 by polymerase chain reaction (PCR) with variable presenting symptoms. The management strategy included Standard of Care (SoC) and administration of hydroxychloroquine and doxycycline. Out of 32 patients, 9 patients also received favipiravir. All patients were followed until they were discharged after negativity of SARS-CoV-2 confirmed by PCR on two consecutive occasions taken within 2 days. RESULTS: No death has been recorded in this cohort of 32 patients within the study period. The average hospital staying duration was 13.9 days with a range of 8–21 days. All patients were discharged with improvement of subjective symptoms and SARS-CoV-2 negativity. The vital signs (pulse, blood pressure) as well as and levels of electrolyte and blood counts were within normal and acceptable ranges at the time of discharge. CONCLUSION: The study presented here provide and evidence of a real-life situation of management of limited numbers of COVID-19 patients at a tertiary center of Bangladesh. This study inspires optimism that proper diagnosis, establishment of effective inclusion and exclusion criteria, ensuring application of proper SoC with drugs available in Bangladesh may be a practical option for management of COVID-19 in the country. HOW TO CITE THIS ARTICLE: Huq AKMF, Rahman MF, Islam MA, et al. Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. Euroasian J Hepato-Gastroenterol 2020;10(1):31–35. Jaypee Brothers Medical Publishers 2020 /pmc/articles/PMC7376598/ /pubmed/32742970 http://dx.doi.org/10.5005/jp-journals-10018-1316 Text en Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd. © The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Article
Faizul Huq, AKM
Rahman, Md Fashiur
Islam, Md Azizul
Iqbal, Syed A
Rahman, Azizur
Abdullah, Syed Abul Hassan Md
Al Mahtab, Mamun
Akbar, Sheikh MF
Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
title Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
title_full Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
title_fullStr Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
title_full_unstemmed Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
title_short Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study
title_sort real-life management strategy of covid-19 patients in bangladesh with no death: an observational and cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376598/
https://www.ncbi.nlm.nih.gov/pubmed/32742970
http://dx.doi.org/10.5005/jp-journals-10018-1316
work_keys_str_mv AT faizulhuqakm reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy
AT rahmanmdfashiur reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy
AT islammdazizul reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy
AT iqbalsyeda reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy
AT rahmanazizur reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy
AT abdullahsyedabulhassanmd reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy
AT almahtabmamun reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy
AT akbarsheikhmf reallifemanagementstrategyofcovid19patientsinbangladeshwithnodeathanobservationalandcohortstudy